-transparent.png){kind=logo}
Clonazepam (CZP) was measured in the plasma of eight subjects for 48 hr after a 0.03-mg/kg oral dose. After pretreatment for 19 days with phenytoin (DPH, 4.3 mg/kg/day), plasma CZP concentrations were determined in the same subjects after another 0.03 mg/kg oral dose of CZP. The same protocol was followed in eight additional subjects using phenobarbital (PB, 1.4 mg/kg/day) instead of DPH. DPH pretreatment lowered mean plasma CZP concentration in 8 of the 12 time points. DPH pretreatment increased CZP clearance by 46% to 58% and decreased CZP half-life (t1/2) by 31%. Both changes were statistically significant. After PB pretreatment the mean plasma CZP concentration was lowered by an average of 11%, but the decrease was statistically significant for only 1 of the 12 time points. PB decreased mean CZP t1/2 by 11% and increased CZP clearance by 19% to 24%, but only the increase in clearance was statistically significant. Both DPH and PB increased CZP clearances and decreased the areas under the plasma concentration-time curves without altering the volumes of distribution. This observation is consistent with induction of CZP metabolism. The overall effect of DPH (4.3 mg/kg/day) was greater than the effect of PB (1.4 mg/kg/day). Neither the DPH or PB had a significant effect on the extent of CZP protein binding.
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
October 1977,
Journal of pharmacokinetics and biopharmaceutics,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
April 1987,
Annals of emergency medicine,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
February 1986,
British journal of clinical pharmacology,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
March 1997,
Journal of the neurological sciences,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
February 2002,
Journal of pediatric hematology/oncology,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
October 1975,
Electroencephalography and clinical neurophysiology,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
October 1982,
Clinical pharmacology and therapeutics,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
August 1996,
Journal of veterinary pharmacology and therapeutics,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
March 1988,
Annals of emergency medicine,
K C Khoo, and
J Mendels, and
M Rothbart, and
W A Garland, and
W A Colburn, and
B H Min, and
R Lucek, and
J J Carbone, and
H G Boxenbaum, and
S A Kaplan
January 1985,
Psychopharmacology,
